PDGFD antibody
- Known as:
- PDGFD (anti-)
- Catalog number:
- orb101253
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- PDGFD antibody
Related genes to: PDGFD antibody
- Gene:
- PDGFD NIH gene
- Name:
- platelet derived growth factor D
- Previous symbol:
- -
- Synonyms:
- SCDGF-B, MSTP036, IEGF
- Chromosome:
- 11q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-01-22
- Date modifiied:
- 2015-08-25
Related products to: PDGFD antibody
Related articles to: PDGFD antibody
- Genetic overlap between any ischaemic stroke (AIS) and coronary artery disease (CAD) can obscure associations less closely tied to coronary risk. We aimed to separate coronary-shared from residual AIS genetic effects. We applied GWAS-by-subtraction to GIGASTROKE AIS and UK Biobank/CARDIoGRAMplusC4D CAD summary statistics. A Cholesky model separated a CAD-related shared component (F1) from a model-defined residual AIS component (F2). We tested model order, factor covariance, population prevalence, CAD input, LD reference and sample-size parameter then characterised loci using FUMA, SuSiE-RSS, genetic correlation, MAGMA, SMR/HEIDI and targeted colocalisation. AIS and CAD had a genetic correlation of 0.490. F1 and F2 had SNP heritabilities of 0.0251 and 0.00414, and F2 contained 14 FUMA loci. F2 Z scores remained correlated across covariance (minimum r = 0.994), prevalence (minimum r = 0.998) and alternative-CAD analyses (r = 0.984). Reverse ordering produced reallocation of source-trait signal. At rs974819, the T allele was associated positively with CAD and negatively with marginal AIS, producing a model-derived CAD-AIS-discordant F2 association. Source-trait colocalisation showed that NBEAL1, PHACTR1 and PDGFD signals were present in one or both input-trait analyses, whereas the F11 protein signal aligned with AIS and F2. In a potentially overlapping FinnGen cross-implementation analysis, all 13 F2 lead variants showed concordant directions. Within overlapping stroke-subtype analyses, F2 showed stronger alignment with cardioembolic stroke. GWAS-by-subtraction resolved a model-defined residual AIS component that was stable across covariance, prevalence and CAD-input specifications, supporting a component-based view of AIS genetic effects after modelling shared coronary architecture. - Source: PubMed
Publication date: 2026/09/01
Wang BinyangWang YuxueYin Yong - Fibrosis development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and limited sample size hinder the identification of consistent and targetable fibrogenic mechanisms. - Source: PubMed
Publication date: 2026/09/16
Maiers Jessica LLiang TiebingGuo TingboCao ShaRamachandran PrakashRaba Teresa JRomeo StefanoJamialahmadi OveisShahrisa Etu ArmanChalasani Naga - Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade cutaneous fibroblastic sarcoma of the dermis that typically presents as a slow-growing red or violet colored plaque. It is classically driven by a collagen type I alpha 1 chain::platelet-derived growth factor subunit B (COL1A1::PDGFB) fusion and is characterized by indolent but locally infiltrative growth with a high risk of local recurrence. Here, we present a 39-year-old woman with a past medical history of breast cancer 1 (BRCA1)/ataxia-telangiectasia mutated (ATM) mutations and invasive lobular carcinoma of the left breast status post bilateral mastectomy, who presented with a tender right calf lump for one year. On physical exam, a well-circumscribed, mobile 2 cm mass was palpated in the right calf without overlying skin changes. Biopsy revealed a CD34-positive, low-grade, cellular, spindle cell neoplasm measuring 2.2 × 1.4 × 0.9 cm, extending to the biopsy margins. Histologically, DFSP is characterized by uniform spindle cells with diffuse CD34 staining. Loss of Rb staining was noted in lesional cells, an atypical finding that initially favored a diagnosis of lipoma over DFSP, complicating the initial differential. Fluorescence in situ hybridization (FISH) analysis for COL1A1 rearrangement was negative, necessitating advanced molecular testing. Solid tumor next-generation sequencing fusion panel identified a COL6A3::PDGFD gene fusion, which accounts for about 2% of DFSP cases. The histologic and molecular findings supported a diagnosis of DFSP with an uncommon translocation. The differential diagnosis included spindle cell lipoma and cellular fibrohistiocytic neoplasm, but these were excluded based on immunohistochemistry and genetic data. Given the extension of lesional cells to biopsy margins, re-excision was performed with negative margins. This case exhibits an atypical presentation of DFSP with a rare COL6A3::PDGFD fusion undetectable by standard FISH, demonstrating the importance of advanced molecular testing in suspected DFSP when FISH is negative for the COL1A1 rearrangement. Additionally, DFSP typically presents on the trunk with overlying skin surface changes, making a calf lesion without cutaneous involvement unusual. - Source: PubMed
Publication date: 2026/07/18
Ruci AmandaSmart Chandra - Platelet-derived growth factors (PDGFs) and their cognate receptors (PDGFRα/β) play critical roles in breast cancer progression and metastasis. This review summarizes current evidence of PDGF ligand and receptor expression patterns, oncogenic functions, prognostic significance and therapeutic targetability, with a specific focus on small molecule inhibition. PDGF-PDGFR signaling is known to contribute to epithelial to mesenchymal transition, cancer stem cell maintenance, desmoplasia, angiogenesis, and immune modulation. Additionally, the four PDGF ligands have distinct oncogenic functions. PDGFA and PDGFB have been implicated in breast cancer associated brain metastasis, while PDGFC has been shown to play a crucial role in fibroblast activation. PDGFD, while less studied, may activate epithelial to mesenchymal transition in breast cancer. High expression of PDGFA, PDGFB, PDGFC, and stromal PDGFRβ correlate with poor patient survival, highlighting their potential as candidate biomarkers. We specifically focus on evaluating current therapeutic strategies which target the PDGF-PDGFR axis, including neutralizing antibodies, aptamers, and small molecule inhibitors, which show preclinical promise but limited clinical success in breast cancer to date. We discuss future research directions with emphasis on identifying selective inhibitors, utilizing PDGF-PDGFR signaling components for patient stratification, and combination with immunotherapies. - Source: PubMed
Publication date: 2026/08/07
Reardon Jesse JMossing Alexis APackard Rebecca LShah SajitaSizemore Gina M - Dermatofibrosarcoma protuberans (DFSP) is a fibroblastic malignancy characterized in most cases by COL1A1::PDGFB fusion. Rare cases exhibit alternative rearrangements involving PDGFD. Here, we describe a female patient in her third decade of life who presented with a spindle cell proliferation on the shoulder. Expression of pan-TRK and S100, together with absence of PDGFB overexpression, supported an initial impression of NTRK-rearranged spindle cell tumor. However, molecular analysis revealed PDGFD rearrangement, and re-excision demonstrated classic DFSP morphology in the residual tumor. Our findings underscore the importance of continued consideration for DFSP in tumors with focal S100 expression. - Source: PubMed
Publication date: 2026/08/04
Podesta VeneziaChan May PRottmann DouglasHarms Kelly LHarms Paul W